Other names: CKS-1; CKS1; PNAS-143; PNAS-16; PNAS-18; ckshs1 HGNC (Hugo): CKS1B Location: 1q21.3
DNA/RNA
Genomic organization of the CKS1B gene.
Description
Three exons, spans approximately 4.61 kb of genomic DNA in the centromere-to-telomere orientation. The translation initiation codon ATG is located in exon 1, and the stop codon in exon 3.
Transcription
mRNA of approximately 1.8 kb. There are two transcript variants for CKS1B gene. The variant 2 uses a different splice site at the 3' end of the first exon compared to variant 1. There is no evidence that variant 2 encodes a protein.
Pseudogene
4 processed, non-expressed, pseudogenes in human genome.
Protein

Description
The open reading frame encodes a 79 amino acid protein, with an estimated molecular weight of approximately 9660 Da. 
677
Expression
Basical level expression in all mammalian cell and aberrant expression in cancer cell.
Localisation
Cytoplasm and nucleus.
Function
CKS1B protein binds to the catalytic subunit of the cyclin dependent kinases and is essential for their biological function of cell cycle control.
Schematic of the regulation of cell cycle by the CKS1B. CKS1B associates with the p27kip1-Cdk/cyclin complex, induces the formation of the p27kip1-SCF ubiquitin ligase complex, triggers degradation of p27kip1, and signals cells to undergo the G1/S transition by releasing and activating the Cdk/cyclin A/E complexes. CycE/A, cyclin E or Cyclin A; Ub, ubiquitin.
Homology
The CKS1B proteins are evolutionary conserved. Mammalian cells express two well-conserved members, like the human CKS1B and CKS2 proteins. The CKSB1B protein is highly conserved across species.
Implicated in
Cancer
Note
The expression of CKS1B is elevaled in multiple cancer, including breast cancer, lymphoma, myeloma, colon cancer, prostate cancer, lung cancer, renal carcinoma, oesophageal squamous cell carcinoma, salivary cancer, serous ovarian cancer, bladder cancer, urothelial carcinoma et al.
Prognosis
Overexpression of CKS1B is associated with poor prognosis in multiple cancer, including myeloma, breast cancer, lymphoma, renal carcinoma, ovarian cancer et al.
Oncogenesis
Amplification and overexpression of CKS1B were strongly associated with lymph node metastasis and poor prognosis in breast, salivary cancer and oesophageal squamous cell carcinoma. Generally, CKS1B is an essential factor in facilitating Skp2-dependent degradation of p27. In breast cancer cell, overexpression of CKS1B may inhibit the apoptosis through the MEK-Erk pathway. All of these suggest that CKS1B alterations may have a significant biological role in the tumorigenesis in different tissue and the novel therapeutic strategy for cancer through inhibiting the CKS1B activity. Therefore, disruption of Skp2-CKS1B assembly or down-regulation of CKS1B expression may be used for cancer therapy.
